[1]葛竑璐,陈 飞,陆跃美,等.自拟扶正消癥汤加减联合呋喹替尼及信迪利单抗方案治疗标准治疗失败后晚期结直肠癌的疗效观察[J].医学信息,2024,37(10):101-104.[doi:10.3969/j.issn.1006-1959.2024.10.020]
　GE Hong-lu,CHEN Fei,LU Yue-mei,et al.Observation on the Efficacy of Self-made Fuzheng Xiaozheng Decoction Combined with Furoquintinib and Sintilimab in the Treatment of Advanced Colorectal Cancer After Standard Treatment Failure[J].Journal of Medical Information,2024,37(10):101-104.[doi:10.3969/j.issn.1006-1959.2024.10.020]
点击复制

自拟扶正消癥汤加减联合呋喹替尼及信迪利单抗方案治疗标准治疗失败后晚期结直肠癌的疗效观察()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年10期
页码:
101-104
栏目:
论著
出版日期:
2024-05-15

文章信息/Info

Title:
Observation on the Efficacy of Self-made Fuzheng Xiaozheng Decoction Combined with Furoquintinib and Sintilimab in the Treatment of Advanced Colorectal Cancer After Standard Treatment Failure
文章编号:
1006-1959（2024）10-0101-04
作者:
葛竑璐; 陈 飞; 陆跃美; 等
（南通市通州区中医院肿瘤内科1，普外科2，内分泌科3，江苏 南通 226300）
Author(s):
GE Hong-lu; CHEN Fei; LU Yue-mei; et al.
(Department of Oncology1,Department of General Surgery2,Department of Endocrinology3,Nantong Tongzhou District Hospitalof Traditional Chinese Medicine,Nantong 226300,Jiangsu,China)
关键词:
扶正消癥汤; 呋喹替尼; 信迪利; 标准治疗; 晚期结直肠癌
Keywords:
Fuzheng Xiaozheng decoction; Furoquintinib; Sintilimab; Standard treatment; Advanced colorectal cancer
分类号:
R273
DOI:
10.3969/j.issn.1006-1959.2024.10.020
文献标志码:
A
摘要:
目的 观察自拟扶正消癥汤加减联合呋喹替尼及信迪利单抗方案治疗标准治疗失败后晚期结直肠癌临床疗效。方法 选取2019年10月-2022年12月在我院诊治的45例标准治疗失败后晚期结直肠癌患者为研究对象，采用随机数字表法分为对照组（n=23）和治疗组（n=22）。对照组采用呋喹替尼+信迪利单抗治疗，治疗组在对照组基础联合应用自拟扶正消癥汤加减治疗，比较两组临床疗效、生活质量水平（QOL）、不良反应发生情况。结果 治疗组疾病控制率为59.09%，与对照组的52.17%比较，差异无统计学意义（P＞0.05）；治疗后治疗组QOL评分为（40.65±5.90）分，对照组为（29.30±4.38）分，分别高于治疗前的（20.31±2.70）分、（19.39±3.12）分，且治疗组高于对照组（P＜0.05）；治疗组各项不良反应发生率均低于对照组（P＜0.05）。结论 标准治疗失败后晚期结直肠癌患者采用自拟扶正消癥汤加减联合呋喹替尼+信迪利单抗方案治疗，可一定程度提高疾病控制率，改善患者生活质量水平，减少不良反应，为患者的良好生存提供有利条件。
Abstract:
Objective To observe the clinical efficacy of self-made Fuzheng Xiaozheng decoction combined with furoquintinib and sintilimab in the treatment of advanced colorectal cancer after standard treatment failure.Methods A total of 45 patients with advanced colorectal cancer after standard treatment failure in our hospital from October 2019 to December 2022 were randomly divided into control (n=23 ) and treatment (n=22) groups. The control group was treated with furoquinitinib+sintilimab, and the treatment group was treated with self-made Fuzheng Xiaozheng decoction on the basis of the control group. The clinical efficacy, quality of life (QOL) and adverse reactions were compared between the two groups.Results The disease control rate of the treatment group was 59.09%, compared with 52.17% of the control group, the difference was not statistically significant (P>0.05); after treatment, the QOL score of the treatment group and the control group was (40.65±5.90)scores and (29.30±4.38)score, respectively, which was higher than (20.31±2.70)scores and (19.39±3.12)scores before treatment, and the treatment group was higher than the control group (P<0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group (P<0.05).Conclusion For patients with advanced colorectal cancer after standard treatment failure, self-made Fuzheng Xiaozheng decoction combined with furoquintinib+sintilimab regimen can improve the disease control rate to a certain extent, improve the quality of life of patients, reduce adverse reactions, and provide favorable conditions for the good survival of patients.

参考文献/References:

[1]陈来恩,郭甜甜,韩飞翔,等.扶正消癥汤佐治胃癌的疗效及对免疫功能和肿瘤标志物的影响[J].癌症进展,2020,18(11):1148-1151.[2]吴春晓,顾凯,龚杨明,等.2015年中国结直肠癌发病和死亡情况分析[J].中国癌症杂志,2020,30(4):241-245.[3]李成,李翠琴.雷替曲塞联合伊立替康二线治疗晚期结直肠癌的临床效果分析[J].宁夏医学杂志,2019,41(11):973-976.[4]田剑波,温艳,杨卓煜,等.全球结直肠癌筛查指南及共识质量评价[J].中华流行病学杂志,2021,42(2):248-257.[5]Hou B,Li W,Li J,et al.Tumor suppressor LHPP regulates the proliferation of colorectal cancer cells via the PI3K/AKT pathway[J].Cancer,2020,43(2):536-548.[6]刘冬博,王勋.健脾益肾补气汤对大肠癌患者术后免疫功能的影响[J].河南中医,2020,40(3):438-441.[7]秦叔逵,杨柳青,李进,等.雷替曲塞单药治疗不能耐受或不适合5-FU/CF治疗的局部晚期或复发转移性结直肠癌的全国多中心Ⅳ期临床研究[J].临床肿瘤学杂志,2017,22(3):203-208.[8]王珍,郑松,徐锡枫,等.改良FOLFOXIRI方案作为三线或三线后方案治疗晚期结直肠癌的回顾性研究[J].中国肿瘤临床,2018,45(14):735-740.[9]王晰程,韦青,高静,等.改良FOLFOXIRI方案治疗晚期结直肠癌的有效性和安全性:21例回顾性研究[J].解放军医学杂志,2019,41(3):248-253.[10]张莉,柯其广,杨伟龙.甲磺酸阿帕替尼对晚期结直肠癌化疗后耐药的改善[J].中国现代普通外科进展,2020,23(9):733-736.[11]刘敏.甲磺酸阿帕替尼三线治疗老年晚期胃癌的效果和不良反应分析[J].河南医学研究,2020,29(36):6835-6837.[12]赵景文,毛刚,王巨良,等.自拟消癌汤合四君子汤治疗晚期转移性直肠癌疗效及对生活质量、血清肿瘤标志物水平的影响[J].现代中西医结合杂志,2020,29(3):308-310,330.[13]Mauri G,Arena S,Siena S,et al.The DNA damageresponse pathway as a land of therapeutic opportunities for colorectal cancer[J].Ann Oncol,2020,31(9):1135-1147.[14]张虹.十全大补汤加减联合化疗治疗进展期胃癌气血虚瘀证的疗效观察[D].福州:福建中医药大学,2021.[15]姬颖华,杨晓煜,王瑾,等.盐酸安罗替尼联合信迪利单抗注射液治疗对微卫星稳定型结直肠癌患者血管内皮生长因子、转化生长因子-β水平及免疫功能的影响[J].癌症进展,2021,19(7):725-728.[16]汤俊,黄春锦,陈玺.老年结直肠癌患者血清内CEA、AFP、CA50、CA199和CA724的表达及意义[J].实用癌症杂志,2019,34(3):397-399,406.[17]戴玲玲,孟鹏,毛俊俊,等.仙芪扶正颗粒联合三焦针法对Ⅲ-Ⅳ期结直肠癌患者免疫及CEA、CA724的影响[J].世界中医药,2020,15(20):3074-3078.[18]邓婧靓,周留敏,周琳.活血解毒汤联合火针治疗血瘀型银屑病疗效及对患者外周血Th1/Th2平衡的影响[J].陕西中医,2019,40(1):103-105.[19]黄浩然,赵杉,王如然,等.扶正消瘤汤对湿热蕴结型晚期结直肠癌术后患者生存率、生活质量及血清白细胞介素6、肿瘤坏死因子α的影响[J].河北中医,2021,43(8):1266-1271.[20]宋庆,张春盈,冯艳亮.扶正消积汤联合化疗治疗晚期结肠癌疗效观察及对肿瘤标记物、免疫功能指标的影响[J].福建中医药,2019,50(3):13-14.

更新日期/Last Update: 1900-01-01